PREDNISOLONE , PARACETAMOL , SILTUXIMAB , ANAKINRA , DIPHENHYDRAMINE , TOCILIZUMAB , DuoBody-CD3xCD30 clinical trials

A Phase 1/2a, Open-label, Dose Escalation Trial of GEN3017 with Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma

This study is testing a new medicine called GEN3017 for people with Hodgkin or non-Hodgkin lymphoma. It's an early-stage trial looking at safe doses and checking for side effects, as well as seeing how well the treatment shrinks the cancer.